The earnings call reflected a positive sentiment overall, with strong financial performance, significant growth in DAYBUE and NUPLAZID sales, and a robust pipeline expansion. However, increased SG&A expenses and challenges in clinical trials were noted as areas of concern.

Company Guidance

During the ACADIA Pharmaceuticals second quarter 2025 conference call, the company reported robust financial performance and growth across its portfolio. Total revenue for the quarter was $264.6 million, a 9% increase year-over-year, driven by sales of DAYBUE and NUPLAZID, which contributed $96.1 million and $168.5 million respectively. DAYBUE sales were up by 14% from the previous year, with a 12-month persistency rate exceeding 50% and an 18-month rate over 45%. NUPLAZID's revenue grew by 7% year-over-year, supported by a successful direct-to-consumer campaign, resulting in a 17% increase in referrals. The company raised the lower end of its NUPLAZID sales guidance to $665 million - $690 million for 2025, reflecting strong performance. R&D expenses for the quarter were $78 million, while SG&A expenses were $133.5 million. ACADIA ended the quarter with a cash balance of $762 million. The company also highlighted its expanding pipeline, with expectations for several Phase II and III studies in the coming years.

Strong Financial Performance

ACADIA achieved total revenue of $264.6 million for the quarter, marking a 9% year-over-year increase.

DAYBUE Growth

DAYBUE net product sales reached $96.1 million, up 14% from the previous year, with a steady increase in patient uptake.

NUPLAZID Performance

NUPLAZID sales were $168.5 million, a 7% year-over-year increase, driven by a 17% rise in referrals and successful direct-to-consumer campaigns.

Pipeline Expansion

9 disclosed programs in development with 5 Phase II or III data readouts expected through 2027. Notable programs include ACP-211 for major depressive disorder and ACP-271 for tardive dyskinesia and Huntington's disease.

Increased Cash Balance

Cash balance increased to $762 million, from $756 million at the end of 2024.

ACADIA Pharmaceuticals (ACAD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ACAD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 11, 2025	2025 (Q3)	0.14 / -	0.2	―	―	―
Aug 06, 2025	2025 (Q2)	0.14 / 0.16	0.2	-20.00% (-0.04)
May 07, 2025	2025 (Q1)	0.09 / 0.11	0.1	10.00% (<+0.01)
Feb 26, 2025	2024 (Q4)	0.22 / 0.86	0.28	207.14% (+0.58)
Nov 06, 2024	2024 (Q3)	0.14 / 0.20	-0.4	150.00% (+0.60)
Aug 06, 2024	2024 (Q2)	0.18 / 0.20	0.01	1900.00% (+0.19)
May 08, 2024	2024 (Q1)	0.05 / 0.10	-0.27	137.04% (+0.37)
Feb 27, 2024	2023 (Q4)	0.29 / 0.28	-0.26	207.69% (+0.54)
Nov 02, 2023	2023 (Q3)	-0.45 / -0.40	-0.17	-135.29% (-0.23)
Aug 02, 2023	2023 (Q2)	-0.10 / 0.01	-0.21	104.76% (+0.22)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ACAD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$23.80	$24.40	+2.52%
May 07, 2025	$14.81	$16.93	+14.31%
Feb 26, 2025	$19.00	$19.34	+1.79%
Nov 06, 2024	$15.79	$17.20	+8.93%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does ACADIA Pharmaceuticals (ACAD) report earnings?

ACADIA Pharmaceuticals (ACAD) is schdueled to report earning on Nov 11, 2025, After Close (Confirmed).

What is ACADIA Pharmaceuticals (ACAD) earnings time?

ACADIA Pharmaceuticals (ACAD) earnings time is at Nov 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ACAD EPS forecast?

ACAD EPS forecast for the fiscal quarter 2025 (Q3) is 0.14.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing